Hypertension or high blood pressure leads to the development of various cardiovascular diseases like heart failure, ischaemic heart disease, haemorrhagic stroke, and ischaemic stroke. One of the forms of hypertension is neurogenic hypertension, which is caused by neuronal mechanisms, including increased sympathetic nerve activity. Lipid mediators like prostanoids, that include prostaglandins and thromboxane, are known to play a key role in various cellular and physiological processes like cell death, inflammations, blood pressure regulation, sleep, cell migration, and bone remodelling. Prostanoids are synthesized from membrane phospholipids through the action of two rate-limiting enzymes, phospholipase A2 (PLA2) and cyclooxygenase (Cox) and leads to the synthesis of different types of prostaglandins like prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α), prostaglandin I2 (PGI2), and prostaglandin J2 (PGJ2). Studies have shown that PGD2, which is the major PG in the brain, increases sympathetic nervous activity and could play a critical role in blood pressure control. In our study, we will identify the specific brain region involved in PGD2 and its receptors DP1 and DP2 signalling in blood pressure control using laboratory animal models of hypertension.